Genen­tech is the lat­est drug­mak­er to sue the fed­er­al gov­ern­ment over STD clin­ics it says are wrong­ful­ly re­ceiv­ing dis­counts through the fed­er­al 340B pro­gram. … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

South Ko­re­an bio­phar­ma con­tract man­u­fac­tur­er Cell­tri­on is con­sid­er­ing ac­quir­ing US man­u­fac­tur­ing sites to mit­i­gate Pres­i­dent Don­ald Trump’s po ...

Two biotech com­pa­nies failed to re­verse or­ders bar­ring them from sell­ing biosim­i­lars of Re­gen­eron’s eye dis­ease drug Eylea in rul­ings from a fed­er­al ap­peals court … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Sage Ther­a­peu­tics knows it needs to do some­thing. But it doesn’t want to sell to its part­ner Bio­gen.

Obe­si­ty drug de­vel­op­er Met­sera and kid­ney dis­ease biotech Maze Ther­a­peu­tics priced their Nas­daq IPOs on Thurs­day evening.

Eli Lil­ly is dis­con­tin­u­ing a Phase 2 re­lax­in treat­ment can­di­date for heart fail­ure and chron­ic kid­ney dis­ease, a spokesper­son for the com­pa­ny con­firmed to … ...

As­traZeneca and Dai­ichi Sankyo’s an­ti­body-drug con­ju­gate En­her­tu is now ap­proved to treat a new sub­set of breast can­cer pa­tients with very low lev­els of HER2 … ...

Ver­tex Phar­ma­ceu­ti­cals and the Na­tion­al Health Ser­vice in Eng­land have reached a pay­ment deal mak­ing the gene-edit­ed ther­a­py Cas­gevy avail­able to cer­tain peo­ple ...

As­traZeneca has can­celed its plans to ex­pand its vac­cine man­u­fac­tur­ing site in Speke, UK, af­ter the new UK gov­ern­ment trimmed fund­ing for the project, a … ...

Ger­man CD­MO Rentschler Bio­phar­ma is clos­ing down its cell and gene ther­a­py op­er­a­tions and shut­ter­ing a fa­cil­i­ty in the UK, which could af­fect up to … ...